Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00268957 · ClinicalTrials.gov registry record · Phase 3
Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 217
- Enrollment target
NCT00268957 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 217 participants.
The verdict
NCT00268957, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 217 participants
- Enrollment target
Study Summary
Approximately 207 patients with chronic kidney disease (CKD) on hemodialysis will be entered into this study at approximately 26 centers in the United States. This study aims to evaluate the safety and efficacy of sevelamer carbonate powder dosed once-a-day (QD) with the largest meal compared to sevelamer hydrochloride tablets dosed three-times-per-day (TID) with meals. The total length of participation is approximately 24 weeks.
Interventions
- DRUG Sevelamer carbonate (Renvela®)
- DRUG Sevelamer hydrochloride (Renagel®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00268957
The ClinicalTrials.gov registry entry for NCT00268957 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sevelamer carbonate (Renvela®) is the first listed.
NCT00268957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00268957 about?
NCT00268957 is a clinical study titled "Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis". Approximately 207 patients with chronic kidney disease (CKD) on hemodialysis will be entered into this study at approximately 26 centers in the United States. This study aims to evaluate the safety and efficacy of sevelamer carbonate powder dosed once-a-day (QD) with the largest meal compared to sev...
What is the current status of trial NCT00268957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 217 participants. The study started on 2006-01. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00268957?
The interventions under investigation include: Sevelamer carbonate (Renvela®) (DRUG), Sevelamer hydrochloride (Renagel®) (DRUG).
Who is sponsoring clinical trial NCT00268957?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.